5NFT

Glucocorticoid Receptor in complex with AZD5423


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.3 Å
  • R-Value Free: 0.215 
  • R-Value Work: 0.186 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.

Hemmerling, M.Nilsson, S.Edman, K.Eirefelt, S.Russell, W.Hendrickx, R.Johnsson, E.Karrman Mardh, C.Berger, M.Rehwinkel, H.Abrahamsson, A.Dahmen, J.Eriksson, A.R.Gabos, B.Henriksson, K.Hossain, N.Ivanova, S.Jansson, A.H.Jensen, T.J.Jerre, A.Johansson, H.Klingstedt, T.Lepisto, M.Lindsjo, M.Mile, I.Nikitidis, G.Steele, J.Tehler, U.Wissler, L.Hansson, T.

(2017) J. Med. Chem. 60: 8591-8605

  • DOI: 10.1021/acs.jmedchem.7b01215
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • A class of potent, nonsteroidal, selective indazole ether-based glucocorticoid receptor modulators (SGRMs) was developed for the inhaled treatment of respiratory diseases. Starting from an orally available compound with demonstrated anti-inflammatory ...

    A class of potent, nonsteroidal, selective indazole ether-based glucocorticoid receptor modulators (SGRMs) was developed for the inhaled treatment of respiratory diseases. Starting from an orally available compound with demonstrated anti-inflammatory activity in rat, a soft-drug strategy was implemented to ensure rapid elimination of drug candidates to minimize systemic GR activation. The first clinical candidate 1b (AZD5423) displayed a potent inhibition of lung edema in a rat model of allergic airway inflammation following dry powder inhalation combined with a moderate systemic GR-effect, assessed as thymic involution. Further optimization of inhaled drug properties provided a second, equally potent, candidate, 15m (AZD7594), that demonstrated an improved therapeutic ratio over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and prolonged the inhibition of lung edema, indicating potential for once-daily treatment.


    Organizational Affiliation

    Respiratory, Inflammation & Autoimmunity, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Pepparedsleden 1, Mölndal, SE 43183, Sweden.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Glucocorticoid receptor
A
280Homo sapiensMutation(s): 6 
Gene Names: NR3C1 (GRL)
Find proteins for P04150 (Homo sapiens)
Go to Gene View: NR3C1
Go to UniProtKB:  P04150
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Nuclear receptor coactivator 2
B
14Homo sapiensMutation(s): 0 
Gene Names: NCOA2 (BHLHE75, SRC2, TIF2)
Find proteins for Q15596 (Homo sapiens)
Go to Gene View: NCOA2
Go to UniProtKB:  Q15596
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
EDO
Query on EDO

Download SDF File 
Download CCD File 
A
1,2-ETHANEDIOL
ETHYLENE GLYCOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
 Ligand Interaction
8W8
Query on 8W8

Download SDF File 
Download CCD File 
A
2,2,2-tris(fluoranyl)-~{N}-[(1~{R},2~{S})-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]ethanamide
C25 H21 F4 N3 O3
FCNQMDSJHADDFT-WNSKOXEYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.3 Å
  • R-Value Free: 0.215 
  • R-Value Work: 0.186 
  • Space Group: P 32 2 1
Unit Cell:
Length (Å)Angle (°)
a = 84.371α = 90.00
b = 84.371β = 90.00
c = 106.119γ = 120.00
Software Package:
Software NamePurpose
BUSTERrefinement
SCALAdata scaling
MOSFLMdata reduction
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2017-03-15 
  • Released Date: 2017-10-04 
  • Deposition Author(s): Edman, K., Wissler, L.

Revision History 

  • Version 1.0: 2017-10-04
    Type: Initial release
  • Version 1.1: 2017-11-08
    Type: Database references